Helix Surgical announces the appointment of Florent Deloison as President. He succeeds François Salin, who is retiring.
The decision was adopted by the Supervisory Board chaired by Eric Mestre on February 17, 2026, and subsequently approved by the Extraordinary General Meeting held on February 19, 2026.
This governance transition comes at a strategic moment for Helix Surgical, as the company reaches a key milestone in its development with the entry into the commercialization phase of its Rx femtolaser.
Previously serving as the company’s Chief Medical Officer, Florent Deloison has played a decisive role in the clinical and technological development of the Rx femtolaser. His scientific expertise and in-depth understanding of regulatory and clinical challenges are major assets in leading the transition toward a structured commercial dynamic.
His academic background reflects a high level of scientific excellence: he studied at Pierre and Marie Curie University (Sorbonne University), earned a Bachelor of Science (Honors) in Physics from the University of Bath, and completed a PhD in ophthalmic laser applications at École Polytechnique, conducting research on laser–ocular tissue interactions.
François Salin stated:
“I am very pleased to hand over the leadership to Florent. Over the past years, he has demonstrated exceptional mastery of our technologies and a deep understanding of market expectations. I am fully confident in his ability to lead Helix Surgical into a new dimension and to successfully execute the commercialization phase that begins today.”
Florent Deloison added:
“I would like to thank François for the structuring work he has accomplished and the Supervisory Board for its trust. Today, Helix Surgical has a differentiated technology and strong assets to enter this new phase. But our true strength lies above all in the exceptional quality of our teams. We are fortunate to bring together women and men of the highest level of expertise, deeply committed, demanding, creative, and driven by a shared ambition to advance surgery through innovation. Their talent, energy, and cohesion form the foundation of our ambition. Today, our priority is clear: to transform our technological excellence into sustainable commercial success, for the benefit of our partners, investors, and practitioners.”
Eric Mestre, Chairman of the Supervisory Board, concluded:
“This succession has been methodically prepared over the past months. It fully aligns with the transition from a development phase to the commercialization of the Rx femtolaser. I am convinced that Florent possesses the strategic vision, scientific rigor, and execution capabilities required to support the company’s growth trajectory and to create value for all shareholders.”
